Clinical trial NCT04705350: A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants
Official title: A Randomized, Participant-Blind, Investigator-Blind, Placebo-Controlled Study Evaluating Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Study Participants
Keywords: Healthy study participants
UCB7858
zampilimab
Phase 1
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2021-01-12
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of zampilimab in healthy study participants.


Eligibility criteria: Inclusion Criteria:

* Participant must be 18 to 55 years of age inclusive, at the time of signing the Informed Consent Form (ICF)
* Study participant must be considered reliable and capable of adhering to the protocol, according to the judgment of the Investigator, and is able to communicate satisfactorily with the Investigator and comply with all clinical study requirements
* Study participant has adequate peripheral venous access
* Study participant has clinical laboratory test results within the reference ranges of the testing laboratory. Study participants with test results that are outside the specified ranges and that are deemed as clinically nonsignificant will be allowed at the discretion of the Investigator
* Study participant is of normal weight as determined by a body mass index between 18 and 32 kg/m\^2, inclusive, with a body weight of at least 50 kg (male) or 45 kg (female) and no greater than 100 kg
* Study participants may be male or female
* Male participants must agree to use contraception during treatment period and for 5 months; female participants of childbearing potential must be not pregnant or breastfeeding and agree to use contraception during the treatment period and for 5 months

Exclusion Criteria:

* Study participant has any medical (acute or chronic) or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the IMP; or interfering with the interpretation of data
* Study participant has a known hypersensitivity to any components of the investigational medicinal product (IMP) as stated in this protocol or participant has a history of moderate to severe allergic reaction to medication(s), including biologics
* Study participant has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or electrocardiogram (ECG), which, in the opinion of the Investigator, may place the participant at risk because of participation in the study
* Study participant has had major surgery (including joint surgery) within 6 months prior to the Screening Period, or has planned surgery within 6 months after IMP
* Study participant has current diagnosis or history of wound healing complications
* Study participant has a history of alcohol and/or drug abuse up to 6 months before the Screening Period
* Study participant has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Period
* Study participant has an active infection during the Screening Period
* Study participant has clinical signs and symptoms consistent with coronavirus disease (COVID-19) or had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) test result within the last 4 weeks prior to the Screening Period or on admission
* Study participant has had a severe course of COVID-19 that required hospitalization
* Study participant has received any prescription or nonprescription medicines, including over the counter (OTC) remedies or herbal and dietary supplements, within 14 days or 5 half-lives of the respective drug, whichever is longer, other than the occasional use of analgesics, such as paracetamol (acetaminophen) or ibuprofen, oral contraceptives, or inhaled corticosteroids for seasonal rhinitis
* Study participant has received treatment with biologic agents (such as monoclonal antibodies (mAbs) including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to dosing
* Study participant has received a vaccination within 8 weeks prior to Day 1; or intends to have a vaccination during the course of the study
* Study participant has participated in another study of a IMP (and/or an investigational device) within the previous 3 months or 5 half-lives prior to the Screening Period, whichever is longer, or is currently participating in another study of a IMP (and/or an investigational device)
* Study participant has positive serology test for hepatitis B surface antigen, hepatitis B core antibodies (both immunoglobulin G (IgG) and IgM), hepatitis C virus antibodies, or antibodies to human immunodeficiency virus type 1 and/or type 2 during the Screening Period

Primary outcomes:
measure: Incidents of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
measure: Maximum intensity of treatment-emergent adverse events (TEAEs) through the Safety Follow-up (SFU) Visit
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Secondary outcomes:
measure: Maximum zampilimab serum concentration (Cmax)
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
measure: Time to maximum zampilimab serum concentration (tmax)
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
measure: Area under the zampilimab serum concentration-time curve from time zero to last quantifiable concentration (AUC0-t)
timeFrame: From Day 1 (Start of Treatment Period) at predefined time points to the last quantifiable concentration (up to 120 days)
measure: Area under the zampilimab serum concentration-time curve from time zero to infinity (AUC)
timeFrame: Day 1 (Start of Treatment Period) at predefined time points (up to 120 days)
measure: Clearance (CL) of zampilimab in serum
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
measure: Apparent volume of distribution during terminal phase (Vz) of zampilimab
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
measure: Apparent terminal half-life (t1/2) of zampilimab
timeFrame: From Day 1 (Start of Treatment Period) to the end of Safety Follow-up (up to 120 days)
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Up0105 001
Study officials:
affiliation: 001 844 599 2273 (UCB)
name: UCB Cares
role: PRINCIPAL_INVESTIGATOR
References: